HIGHLIGHTS
- who: Jennifer B. Shah from the Acquisition of tumor, germline, and normal tissue specimens from BRCA1/, mutation carriers Patients gave written informed consent for research use of germline DNA, tumor specimens, and clinical data-including the publication of patient age, under IRB approved protocol at the University of Pennsylvania and Vall d`HebronParticipants were not compensated. Eligible patients met the following criteria: (1) diagnosis of breast or ovarian cancer have published the article: Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers, in the Journal: (JOURNAL) of 23/07/2021
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.